更新于：2024-11-21

Amlodipine Besylate/Atenolol

苯磺酸氨氯地平/阿替洛尔

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

Amlodipine/atenolol、Atenolol/amlodipine

靶点

L-type calcium channel x β1-adrenergic receptor

作用机制

L-type calcium channel阻滞剂(L-型电压门控性钙通道家族阻滞剂)、β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)

治疗领域

心血管疾病

在研适应症-

非在研适应症

原发性高血压

原研机构

华润双鹤药业股份有限公司

在研机构-

非在研机构

华润双鹤药业股份有限公司

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C26H31ClN2O8S

InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N

CAS号111470-99-6

查看全部结构式(2)

关联

项与苯磺酸氨氯地平/阿替洛尔相关的临床试验

CTR20131593 / Completed临床2期

苯磺酸氨氯地平阿替洛尔治疗轻中度原发高血压的多中心随机双盲双模拟阳性药对照固定剂量平行组设计II期临床

在轻、中度原发性高血压患者中评价不同剂量苯磺酸氨氯地平和阿替洛尔联合用药所组成的治疗方案与苯磺酸氨氯地平5mg和阿替洛尔25mg单药治疗方案相比的降压疗效

开始日期2012-07-31

申办/合作机构

华润双鹤药业股份有限公司

100 项与苯磺酸氨氯地平/阿替洛尔相关的临床结果

登录后查看更多信息

100 项与苯磺酸氨氯地平/阿替洛尔相关的转化医学

登录后查看更多信息

100 项与苯磺酸氨氯地平/阿替洛尔相关的专利（医药）

登录后查看更多信息

项与苯磺酸氨氯地平/阿替洛尔相关的文献（医药）

2009-01-01·Kardiologiia4区 · 医学

[An experience of the use of a fixed atenolol amlodipine combination in real clinical practice: results of multicenter Russian study].

4区 · 医学

Article

作者: Andrushchishina, T B ; Morozova, T E

AIMTo assess clinical, hemodynamic efficacy and tolerability of a Fixed Atenolol Amlodipine Combination (FAAC) in patients with arterial 1-3 degree arterial hypertension as mono- or combination therapy.MATERIAL AND METHODSAntihypertensive efficacy and tolerability of FAAC was investigated in open noncomparative study in 22 centers in 17 cities of Russia on 570 patients (246 men, 324 women) aged 18-65 years (mean 55,53+8,55 years) with 1-3 degree arterial hypertension. Methods of control included office blood pressure (BP) measurement, 24-hour BP monitoring, electrocardiography, control of biochemical parameters, assessment of efficacy and tolerability.RESULTSAchivement of target BP level at the background of treatment was noted in 401 patients (70.35%) including 171 (30%) patients on monotherapy with FAAC and 230 (40,35%) patients on combination therapy with FAAC and other antihypertensive drug. After 60 days of monotherapy with FAAC according to data of office measurements systolic BP (SBP) decreased from 161.90+/-14,51 to 129.96+/-8,76 mm Hg (p<0.01), diastolic BP (DBP) decreased from 97.61+/-7.45 to 80.04+/-6.44 mm Hg (<0.01). Significant lowering of heart rate from 79.25+/-9.78 to 65.24+/-7.35 bpm (p<0.01) was also noted. After use of combination of FAAC with other antihypertensive drugs according to data of office measurements SBP decreased from 168.24+/-16,78 to 129.77+/-9.55 mm Hg (p<0.01), DBP decreased from 99.66+/-10.03 to 81.36+/-6.51 mm Hg (<0.01). Heart rate decreased from 80.79+/-10.51 to 66.09+/-8.37 bpm (p<0.01). According to data of 24-hour BP monitoring significant lowering of mean 24-hour, diurnal and nocturnal systolic and diastolic BP as well as of hypertensive burden were also noted. No statistically significant dynamics of laboratory parameters was registered during 60 days of therapy with Tenochek. Tolerability was good in 94% of patients, adverse events with premature withdrawal of the drug took place in 1.4% of patients.

100 项与苯磺酸氨氯地平/阿替洛尔相关的药物交易

登录后查看更多信息